CN108310447A - A kind of bacteriolyze enzyme modification hospital gauze - Google Patents
A kind of bacteriolyze enzyme modification hospital gauze Download PDFInfo
- Publication number
- CN108310447A CN108310447A CN201810238230.XA CN201810238230A CN108310447A CN 108310447 A CN108310447 A CN 108310447A CN 201810238230 A CN201810238230 A CN 201810238230A CN 108310447 A CN108310447 A CN 108310447A
- Authority
- CN
- China
- Prior art keywords
- gauze
- enzyme modification
- aqueous solution
- bacteriolyze enzyme
- hospital gauze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009144 enzymatic modification Effects 0.000 title claims abstract description 36
- 239000007864 aqueous solution Substances 0.000 claims abstract description 42
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 102000016943 Muramidase Human genes 0.000 claims abstract description 22
- 108010014251 Muramidase Proteins 0.000 claims abstract description 22
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 22
- 229960000274 lysozyme Drugs 0.000 claims abstract description 22
- 239000004325 lysozyme Substances 0.000 claims abstract description 22
- 239000002253 acid Substances 0.000 claims abstract description 21
- 229920000742 Cotton Polymers 0.000 claims abstract description 19
- 238000002791 soaking Methods 0.000 claims abstract description 19
- 238000005238 degreasing Methods 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000008367 deionised water Substances 0.000 claims abstract description 9
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000005406 washing Methods 0.000 claims abstract description 9
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims description 21
- 150000004714 phosphonium salts Chemical class 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 238000002386 leaching Methods 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 29
- 206010052428 Wound Diseases 0.000 abstract description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000005540 biological transmission Effects 0.000 abstract description 6
- 238000005213 imbibition Methods 0.000 abstract description 6
- 230000029663 wound healing Effects 0.000 abstract description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 4
- 229930003268 Vitamin C Natural products 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract description 4
- 235000019154 vitamin C Nutrition 0.000 abstract description 4
- 239000011718 vitamin C Substances 0.000 abstract description 4
- 230000002924 anti-infective effect Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 206010021703 Indifference Diseases 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- QEDXSHCYPROEOK-UHFFFAOYSA-N 3-phosphanylpropanoic acid Chemical class OC(=O)CCP QEDXSHCYPROEOK-UHFFFAOYSA-N 0.000 abstract 1
- 239000003643 water by type Substances 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- CUXQLKLUPGTTKL-UHFFFAOYSA-M microcosmic salt Chemical compound [NH4+].[Na+].OP([O-])([O-])=O CUXQLKLUPGTTKL-UHFFFAOYSA-M 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002103 nanocoating Substances 0.000 description 1
- 239000002120 nanofilm Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
Abstract
In Lysozyme in Aqueous Solution and three (2 carboxyethyl) phosphonium salt acid salt aqueous solution volume ratios it is 1 by degreasing cotton gauze the invention discloses a kind of bacteriolyze enzyme modification hospital gauze:Soaking at room temperature in 1 mixed liquor takes out gauze after having impregnated, with deionized water soaking and washing, drying to get to bacteriolyze enzyme modification hospital gauze.The bacteriolyze enzyme modification hospital gauze of the present invention has following characteristics：(1) before modified after gauze water imbibition and water vapo(u)r transmission energy indifference；(2) compared with unmodified gauze, bacteriolyze enzyme modification hospital gauze, with after the processing of vitamin C aqueous solution, is easily removed from wound before replacement, be can avoid causing secondary injury to wound in replacement process, is mitigated Principle of Pain；(3) compared with unmodified gauze, bacteriolyze enzyme modification hospital gauze has the function of that sterilization is anti-infective, accelerates wound healing；(4) preparation process is simply mild, at low cost, is suitble to large-scale production.
Description
Technical field
The invention belongs to wound dressing surface technical field of modification, specifically bright to be related to a kind of bacteriolyze enzyme modification hospital gauze.
Background technology
Skin is the maximum organ of human body, is the natural cover for defense for protecting body.For serious defect of skin patient, body fluid
Be largely lost with wound infection be threaten patient vitals principal element, interim covering of the wound dressing as wound can
Metastable healing environment is provided for the surface of a wound, is played a crucial role during wound healing.Traditional absorbent cotton
Gauze is extensive with raw material sources, prepares the significant advantages such as simple, of low cost, and the clinic for being widely used in all kinds of wounds is controlled
It treats.However, the following disadvantage of normal gauze limits its application in terms of complicated wound especially chronic wounds：First, right
There is adhesion effect in wound (especially infected wound), thus secondary insult easily is caused to wound in daily replacement process, gives
Patient brings pain；Secondly, from the point of view of gauze molecular structure, do not have antibacterial action.Therefore, it is a kind of not to be highly desirable exploitation
Adhesion wound is provided simultaneously with and sterilizes the anti-infective novel gauze for promoting wound healing.
Current clinically common petrolatum gauze can effectively prevent gauze to bond wound, but it absorbs sepage ability
And water vapo(u)r transmission can be declined.Strong determined person et al. discloses a kind of medical not viscous yarn in patent CN88102987.4
The characteristics of cloth, adherent layer form with organic silicon emulsion, polyethylene glycol, sulfonated castor oil, ethylene glycol and water, this gauze be
Nontoxic, tasteless, ventilative, good hygroscopicity is not suitable for wrapping up various wounds, but does not have sterilizing function with surface of a wound adhesion.Zhu
Moral its et al. a kind of anti-sticking gauze of novel antibacterial is disclosed in patent CN201320089545.5, using nano-silver sterile layer
It as antibiotic layer, prevents from infecting, improves the safety of gauze；Hemispherical projections are uniformly arranged below in bottom, make bottom
Certain distance is kept with wound, enhances the gas permeability of gauze, while making when opening gauze, sufferer will not be by secondary wound
Evil.But this anti-sticking gauze of antibacterial includes multilayered structure, preparation process is complex.Further, since silver nano-grain can be
Enrichment, the developed countries such as America and Europe have gradually forbidden the use of nano silver in vivo.
(the 2- carboxylics of a certain amount of disulfide bond reducing agent three are added in Shaanxi Normal University Yang Peng et al. discoveries in Lysozyme in Aqueous Solution
Base ethyl) microcosmic salt hydrochlorate, phase transition can quickly occur in the water phase benign environment close to physiological condition for lysozyme carries out
Amyloid assembles, and is firmly adhered in a variety of materials (inorganic, organic, metal, polymer etc.) surface and interface, forms secured, uniform, cause
Close functional nano coating (D.Wang, Y.Ha, J.Gu, Q.Li, L.L.Zhang, P.Yang.2D protein
supramolecular nanofilm with exceptionally large area and emergent
functions.Adv.Mater.2016,28,7414-7423).The protein attribute of lysozyme itself determines the life of the coating
Object compatibility and degradability, the positive charge and a large amount of hydrophobic microcells that coating surface is carried, can be with microbial film surface phase interaction
With cell wall is destroyed, reach efficient contact sterilization effect (J.Gu, Y.J.Su, P.Liu, P.Li, P.Yang.An
Environmentally Benign Antimicrobial Coating Based on a Protein
Supramolecular Assembly.ACS Appl.Mater.Interfaces 2017,9,198-210).Therefore, it is based on molten
The bionic adhesion of bacterium enzyme amyloid assemble nanometer film not only have the characteristics that it is environmentally protective, efficiently it is convenient, flexibly it is controllable, also
With the advantages such as water white transparency, efficient stable, Nantural non-toxic, biodegradable, shown in terms of the modification of hospital gauze surface
Huge potentiality.
Invention content
, preparation process complexity poor for existing anti-adhesive gauze water imbibition and water vapo(u)r transmission energy and nano silver are unfavorable for people
Kind of starch sample easily occurs under the effect of three (2- carboxy ethyls) microcosmic salt hydrochlorates and turns for the problem of body health, binding lysozyme of the present invention
Become, assembles adherency in the surface of solids and lysozyme coating has the characteristics of high-efficient contact formula sterilization, provide a kind of lysozyme and change
Property hospital gauze.
Bacteriolyze enzyme modification hospital gauze is used by solving above-mentioned technical problem：Degreasing cotton gauze is water-soluble in lysozyme
Three (2- carboxyethyls) the phosphonium salt acid salt aqueous solution volume ratios that liquid is 5~10 with pH value are 1:Soaking at room temperature in 1 mixed liquor is impregnated
Gauze is taken out after complete, with deionized water soaking and washing, drying to get to bacteriolyze enzyme modification hospital gauze.
A concentration of 0.5~12mg/mL of above-mentioned Lysozyme in Aqueous Solution, preferably lysozyme concentration are 2~5mg/mL.
A concentration of 10~the 100mmol/L of three above-mentioned (2- carboxyethyls) phosphonium salt acid salt aqueous solutions, preferably three (2- carboxylic second
Base) a concentration of 40~60mmol/L of phosphonium salt hydrochlorate.
It is 5 that three above-mentioned (2- carboxyethyls) phosphonium salt acid salt aqueous solutions, which are with the sodium hydrate aqueous solution adjusting pH value of 5mol/L,
~10, it is 6~8 preferably to adjust pH value.
The above-mentioned soaking at room temperature time is 30~60 minutes.
The present invention has the advantages that：
1, due to not destroying the body construction of gauze, lysozyme before modified after gauze water imbibition and water vapo(u)r transmission energy
Indifference.
2, compared with unmodified gauze, bacteriolyze enzyme modification hospital gauze of the invention uses vitamin C aqueous solution before replacement
It after processing, is easily removed from wound, can avoid causing secondary injury to wound in replacement process, mitigate Principle of Pain.
3, compared with unmodified gauze, bacteriolyze enzyme modification gauze of the invention, which has, sterilizes anti-infective, quickening wound healing
Effect.
4, bacteriolyze enzyme modification gauze preparation process of the invention is simply mild, at low cost, is suitble to large-scale production.
Description of the drawings
Fig. 1 is the electron scanning micrograph of the degreasing cotton gauze in embodiment 1 before modified.
Fig. 2 is the electron scanning micrograph of bacteriolyze enzyme modification hospital gauze prepared by embodiment 1.
Fig. 3 is the water imbibition knot of the bacteriolyze enzyme modification hospital gauze of the degreasing cotton gauze and preparation in embodiment 1 before modified
Fruit.
Fig. 4 is that the vapor of the bacteriolyze enzyme modification hospital gauze of the degreasing cotton gauze and preparation in embodiment 1 before modified is saturating
Cross results of property.
Fig. 5 is the bacteriolyze enzyme modification hospital gauze of the degreasing cotton gauze and preparation in embodiment 1 before modified from mouse wound
Remove exerted oneself size.
Fig. 6 be in blank group, degreasing cotton gauze group before modified, bacteriolyze enzyme modification hospital gauze group mouse wound area with
Time changing curve.
Specific implementation mode
The present invention is described in more detail with reference to the accompanying drawings and examples, but protection scope of the present invention is not limited only to
These embodiments.
Embodiment 1
50mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution is adjusted to pH value with the sodium hydrate aqueous solution of 5mol/L
It is 6.2.Take 10mL 2mg/mL Lysozyme in Aqueous Solution (20mg lysozymes are added in 10mL deionized waters and are formulated) and 10mL
50mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution of pH=6.2 mixes, and it is molten that degreasing cotton gauze is then dipped into mixing
In liquid, soaking at room temperature takes out gauze after sixty minutes, and with deionized water soaking and washing 3 times, 60 DEG C of drying obtain bacteriolyze enzyme modification doctor
Use gauze.
Using scanning electron microscope to before modified degreasing cotton gauze and bacteriolyze enzyme modification hospital gauze characterize, tie
Fruit sees Fig. 1 and 2.As seen from the figure, modified gauze surface covers one layer of lysozyme nanometer film.
According to the absorbent cotton of national standard YY/T 0471.1-2004 and YY/T 0471.2-2004 the methods test before modified
The water imbibition and water vapo(u)r transmission energy, result of gauze and bacteriolyze enzyme modification hospital gauze are as shown in Figure 3 and Figure 4.It can by figure
See, before modified the water imbibition and water vapo(u)r transmission energy no significant difference of rear gauze.
Using mouse full thickness dermal wounds model, after comparison is handled on the 3rd day with 250mmol/L vitamin C aqueous solutions,
Degreasing cotton gauze and bacteriolyze enzyme modification hospital gauze before modified removes exerted oneself size from wound, and the results are shown in Figure 5.
As seen from the figure, modified gauze is easily removed from wound with after the processing of vitamin C aqueous solution before replacement.
Using mouse full thickness dermal wounds model, with blank group, degreasing cotton gauze group compares before modified, observes bacteriolyze
Influence of the enzyme modification hospital gauze to wound healing, each group mouse wound area is as shown in Figure 6 within the 1st, 3,5,7 day.As seen from the figure,
Modified gauze has the function of accelerating wound healing.
Embodiment 2
50mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution is adjusted to pH value with the sodium hydrate aqueous solution of 5mol/L
It is 5.Take 10mL 2mg/mL Lysozyme in Aqueous Solution (20mg lysozymes are added in 10mL deionized waters and are formulated) and 10mL
50mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution of pH=5 mixes, and degreasing cotton gauze is then dipped into mixed solution
In, soaking at room temperature takes out gauze after sixty minutes, and with deionized water soaking and washing 3 times, it is medical to obtain bacteriolyze enzyme modification for 60 DEG C of drying
Gauze.
Embodiment 3
10mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution is adjusted to pH value with the sodium hydrate aqueous solution of 5mol/L
It is 8.Take 10mL 0.5mg/mL Lysozyme in Aqueous Solution (5mg lysozymes are added in 10mL deionized waters and are formulated) and 10mL
10mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution of pH=8 mixes, and degreasing cotton gauze is then dipped into mixed solution
In, soaking at room temperature takes out gauze after sixty minutes, and with deionized water soaking and washing 3 times, it is medical to obtain bacteriolyze enzyme modification for 60 DEG C of drying
Gauze.
Embodiment 4
40mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution is adjusted to pH value with the sodium hydrate aqueous solution of 5mol/L
It is 7.Take 10mL 1mg/mL Lysozyme in Aqueous Solution (10mg lysozymes are added in 10mL deionized waters and are formulated) and 10mL
40mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution of pH=7 mixes, and degreasing cotton gauze is then dipped into mixed solution
In, soaking at room temperature takes out gauze after sixty minutes, and with deionized water soaking and washing 3 times, it is medical to obtain bacteriolyze enzyme modification for 60 DEG C of drying
Gauze.
Embodiment 5
60mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution is adjusted to pH value with the sodium hydrate aqueous solution of 5mol/L
It is 7.Take 10mL 5mg/mL Lysozyme in Aqueous Solution (50mg lysozymes are added in 10mL deionized waters and are formulated) and 10mL
60mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution of pH=7 mixes, and degreasing cotton gauze is then dipped into mixed solution
In, soaking at room temperature takes out gauze after sixty minutes, and with deionized water soaking and washing 3 times, it is medical to obtain bacteriolyze enzyme modification for 60 DEG C of drying
Gauze.
Embodiment 6
100mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution is adjusted to pH value with the sodium hydrate aqueous solution of 5mol/L
It is 10.Take 10mL 12mg/mL Lysozyme in Aqueous Solution (by 120mg lysozymes be added 10mL deionized waters in be formulated) and
100mmol/L tri- (2- carboxyethyls) phosphonium salt acid salt aqueous solution of 10mL pH=10 mixes, and is then dipped into degreasing cotton gauze mixed
It closes in solution, soaking at room temperature takes out gauze after 30 minutes, and with deionized water soaking and washing 3 times, 60 DEG C of drying obtain lysozyme and change
Property hospital gauze.
Claims (8)
1. a kind of bacteriolyze enzyme modification hospital gauze, it is characterised in that：By degreasing cotton gauze Lysozyme in Aqueous Solution and pH value be 5~
10 three (2- carboxyethyls) phosphonium salt acid salt aqueous solution volume ratios are 1:Soaking at room temperature in 1 mixed liquor takes out gauze after having impregnated,
With deionized water soaking and washing, drying to get to bacteriolyze enzyme modification hospital gauze.
2. bacteriolyze enzyme modification hospital gauze according to claim 1, it is characterised in that：The concentration of the Lysozyme in Aqueous Solution
For 0.5~12mg/mL.
3. bacteriolyze enzyme modification hospital gauze according to claim 2, it is characterised in that：The concentration of the Lysozyme in Aqueous Solution
For 2~5mg/mL.
4. bacteriolyze enzyme modification hospital gauze according to claim 1, it is characterised in that：Three (2- carboxyethyls) phosphonium salts acid
A concentration of 10~100mmol/L of saline solution.
5. bacteriolyze enzyme modification hospital gauze according to claim 4, it is characterised in that：Three (2- carboxyethyls) phosphonium salts acid
A concentration of 40~60mmol/L of saline solution.
6. bacteriolyze enzyme modification hospital gauze according to claim 1, it is characterised in that：Three (2- carboxyethyls) phosphonium salts acid
It is 5~10 that the saline solution sodium hydrate aqueous solution of 5mol/L, which adjusts pH value,.
7. bacteriolyze enzyme modification hospital gauze according to claim 6, it is characterised in that：Three (2- carboxyethyls) phosphonium salts acid
It is 6~8 that the saline solution sodium hydrate aqueous solution of 5mol/L, which adjusts pH value,.
8. according to the bacteriolyze enzyme modification hospital gauze described in claim 1~7 any one, it is characterised in that：The room temperature leaching
It is 30~60 minutes to steep the time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810238230.XA CN108310447A (en) | 2018-03-22 | 2018-03-22 | A kind of bacteriolyze enzyme modification hospital gauze |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810238230.XA CN108310447A (en) | 2018-03-22 | 2018-03-22 | A kind of bacteriolyze enzyme modification hospital gauze |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108310447A true CN108310447A (en) | 2018-07-24 |
Family
ID=62898942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810238230.XA Pending CN108310447A (en) | 2018-03-22 | 2018-03-22 | A kind of bacteriolyze enzyme modification hospital gauze |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108310447A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111296926A (en) * | 2020-02-24 | 2020-06-19 | 青岛领军新材料科技创新园发展有限公司 | Graphene protective mask filter element and production process thereof |
| CN114557910A (en) * | 2022-04-08 | 2022-05-31 | 西安交通大学 | Persistent whitening antibacterial mouth wash and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550818A (en) * | 2013-11-07 | 2014-02-05 | 海安县美佳卫生用品有限公司 | Preparation method of medical sterile gauze |
| CN105475359A (en) * | 2015-11-24 | 2016-04-13 | 陕西师范大学 | Application of two-dimensional lysozyme nanometer film as antibacterial material |
-
2018
- 2018-03-22 CN CN201810238230.XA patent/CN108310447A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550818A (en) * | 2013-11-07 | 2014-02-05 | 海安县美佳卫生用品有限公司 | Preparation method of medical sterile gauze |
| CN105475359A (en) * | 2015-11-24 | 2016-04-13 | 陕西师范大学 | Application of two-dimensional lysozyme nanometer film as antibacterial material |
Non-Patent Citations (1)
| Title |
|---|
| 王瑞铭等: "四期压疮患者的门诊换药及护理1例", 《武警医学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111296926A (en) * | 2020-02-24 | 2020-06-19 | 青岛领军新材料科技创新园发展有限公司 | Graphene protective mask filter element and production process thereof |
| CN114557910A (en) * | 2022-04-08 | 2022-05-31 | 西安交通大学 | Persistent whitening antibacterial mouth wash and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5075811B2 (en) | Method for producing antimicrobial wound dressing and use thereof | |
| CN103948960B (en) | A kind of containing nanometer silver porous silicone rubber/polyurethane double-layered artificial skin and preparation method thereof | |
| CN100427149C (en) | Nano silver bionic dressing and its preparing method | |
| EP3672655A1 (en) | Biomaterial and methods of making and using said biomaterial | |
| CN107029272A (en) | A kind of alginate medical dressing and preparation method thereof | |
| CN104758977A (en) | An alginate dressing for treating bedsore and a preparing method thereof | |
| CN103263434B (en) | Anti-adhesion liquor for wound washing and surgery and preparation method and application of anti-adhesion liquor | |
| JPS60122568A (en) | Hydrophilic biopolymer copolyelectrolyte | |
| CN110507845A (en) | Biological composite ventilating dressing and preparation method thereof | |
| CN107456321B (en) | A kind of nanometer silver antimicrobial sanitary napkin and its production method | |
| CN108815564A (en) | A kind of starch base styptic powder and preparation method thereof | |
| CN106659817A (en) | Wound dressing | |
| CN102284081A (en) | Aquagel dressing | |
| WO2024012190A1 (en) | Double-layer bionic drug-loaded hydrogel, and preparation and use thereof | |
| CN109331215A (en) | A kind of medical antibacterial sponge and preparation method thereof | |
| CN104436279A (en) | Preparation method for medical biological antiseptic chitosan dressing | |
| CN103271794A (en) | Biological antibacterial patch for bedsore surface | |
| CN108310447A (en) | A kind of bacteriolyze enzyme modification hospital gauze | |
| CN203576752U (en) | Novel calcium-alginate povidone-iodine-powder spunlaced non-woven fabrics dressing | |
| EP2916879B1 (en) | Wound care device | |
| CN109453411A (en) | A kind of chitosan dressing | |
| EP1487506B1 (en) | Preparation for wound healing and prevention of bandage adhesion to the wound | |
| CN106535947A (en) | Wound dressing | |
| CN110507842A (en) | A kind of bacteria cellulose/hyaluronic acid/epsilon-polylysine functional form dressing and preparation method thereof | |
| JP4486304B2 (en) | Microbial cellulosic wound dressings for the treatment of chronic wounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180724 |
|
| RJ01 | Rejection of invention patent application after publication |